Hidehito Horinouchi: Reconsidering the cutoff for sensitive and refractory relapses in ES-SCLC in the era of ICIs in JTO and JTO CRR by Dr. Masahiro Torasawa.

Hidehito Horinouchi, Assistant Chief of the Department of Thoracic Oncology at National Cancer Center Hospital, shared a post on Twitter:

“JUST ACCEPTED: Reconsidering the cutoff for sensitive and refractory relapses in ES-SCLC in the era of ICIs in JTO and JTO CRR by Dr. Masahiro Torasawa. The 75-day cutoff most accurately predicts subsequent prognosis.

Abstract 8576: Reconsidering the cutoff between sensitive and refractory relapses in ES-SCLC in the era of immunotherapy by Dr. Masahiro Torasawa. The optimal cutoff value is 75 days. Traditional cutoff (60 or 90 days) remains valid as well.

For the articles attached to the post click here and here.”

Source: Hidehito Horinouchi/Twitter